Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2443-2452

  Avnet, Sofia ^a,b   Sciacca, Laura ^c   Salerno, Manuela ^a   Gancitano, Giovanni ^a   Cassarino, Maria Francesca ^c   Longhi, Alessandra ^a   Zakikhani, Mahvash ^d   Carboni, Joan M ^e   Gottardis, Marco ^e   Giunti, Armando ^a,b   Pollak, Michael ^d   Vigneri, Riccardo ^c   Baldini, Nicola ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d MCGILL UNIVERSITY   (Canada)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR ISOFORM A; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; IGFBP3 PROTEIN, HUMAN; INSULIN; ISOPROTEIN; PROTEIN TYROSINE KINASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ARTICLE; AUTOCRINE EFFECT; BLOOD SAMPLING; CANCER INHIBITION; CANCER SURGERY; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; BLOOD; BONE TUMOR; CELL GROWTH; CHILD; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADOLESCENT; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; OSTEOSARCOMA; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 65549161522     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2645     Document Type: Article

References (49)

1. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report J Clin Oncol 2000;18:4016-27.
2. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006:32:423-36.
3. Lewis VO. What's new in musculoskeletal oncology, J Bone Joint Surg Am 2007;89:1399-407.
4. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al. Expression of P-glycoprotein in higli-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
5. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
6. Patanè S, Avnet S, Coltella K, et al. MET over-expression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006;66:4750-7.
7. Lee N, Smolarz AJ, Olson S, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007;97:1552-9.
8. Fraumeni jF, jr. Stature and malignant tumors of bone in childhood and adolescence. Cancer 1967;20:967-73.
9. Cotterill SJ, Wright CM, Pearce MS, Craft AW; UKCCSG/MRC Bone Tumour Working Group. Stature of young people with malignant bone tumors. Pediatr Blood Cancer 2004;42:59-63.
10. Longhi A, Pasini A, Cicognani A, et. al. Height, as a risk factor for osteosarcoma. J Pediatr Hematol Oncol 2005;27:314-8.
11. Sekyi-Otu A Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res 1995;55:129-34.
12. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-52.
13. LeRoith D, Baserga R, Helman L, Roberts CT, Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
14. Pollak MN, Polychronakos C, Richard M. Insulin-like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990;82:301-5.
15. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84:966-71.
16. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-7.
17. MacEwen EG, Pastor J, Kutzke j, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
18. Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 1999;80:581-8.
19. Bautista CM, Baylink DJ, Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF- II in human bone. Biochem Biophys Res Commun 1991;176:756-63.
20. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
21. Ohlaaon R, Nystrom A, Pfeifer-Ohlsson S, et al. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann sindrome. Nat Genet 1993;4:94-7.
22. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP, Relaxation of imprinted genes in human cancer. Nature 1993;362:747-9.
23. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993;362:749-51.
24. Ulaner GA, Vu TH, Li T, et al. Loss of Imprinting of IGF2 and HI9 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003;12:535-49.
25. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88.
26. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002;21:8240-50.
27. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpres- sion in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-44.
28. Slaaby R, Schäffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by Insulin receptor (IRJ and insulin-like growth factor I receptor (IGFIR) have low Insulin and high IGF-1 affinity irrespective of the IR splice variant, J Biol Chem 2006;281:25869-74.
29. Pandini G, Medico E, Conte E, Sciacca L, Vigneri R, Relfiore A. Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor Isoform A. J Biol Chem 2003;278:42178-89.
30. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma-prellminary results of the Rizzolis 4th study. Acta Oncol 1998;37:41-8.
31. Sciacca L, Prisco M, Wu A, Relfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology 2003;144:2650-8.
32. Chen-J, Wu A, Sun H, et al. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the Insulin receptor substrate-1 and β-catenin. J Biol Chem 2005;280:29912-20.
33. Wittman M, Carboni J, Attar R, et al. The discovery of a small molecule inhibitor of IGF-1R with broad spectrum in vivo activity. J Med Chem 2005;48:5639-43.
34. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenlcity. Lab Invest 1995;73:311-31.
35. Rodriguez-Galindo C, Poquette CA, Daw NC, Tan M, Meyer WH, Cleveland JL. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behaviour of pediatric osteosarcoma. Med Pediatr Oncol 2001;36:605-11.
36. Middleton J, Arnott N, Walsh S, Beresford J. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type I IGF receptor. Bone 1995;16:287-93.
37. Conover CA. The role of Insulin-like growth factors and binding proteins in bone cell biology. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. San Diego (CA): Academic Press; 1996. p. 607-18.
38. Mohan S, Jennings JC, Linkhart TA, Baylink DJ. Primary structure of human skeletal growth factor: homology with human insulin-like growth factor-II. Biochim Biophys Acta 1988;966:44-55.
39. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336:633-40.
40. Mohan S, Baylink DJ. The role of Insulin-like growth factor I and II in the autocrine/paracrine regulation of bone-cell metabolism In: Novak JK, McMaster JH, editors. Frontiers of Osteosarcoma research. Seattle: Hoegrefe & Huber Publishers; 1993. p. 477-88.
41. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 1988;319:1434-40.
42. Garrone S, Radetti G, Sidoti M, Bozzola M, Minuto F, Barreca A Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tell children. J Clin Endocrinol Meteb 2002;87:5455-60.
43. Moller DE( Yokota A, Caro JE, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989;3:1263-9.
44. Jonas HA, Newman JD, Harrison LC. An atypical insulin receptor with high affinity for insulin-like growth factors copurified with placental insulin receptors. Proc Natl Acad Sci USA 1986;83:4124-8.
45. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development Dev Biol 1997;189:33-48.
46. Vella V, Mineo R, Frasca F, et al. Interleukin-4 stimulates papillary thyroid cancer cell survival: Implications in patients with thyroid cancer and concomitant Graves' disease. J Clin Endocrinol Metab 2002;87:45-254.
47. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 2003;35:778-85.
48. Sun Y, Gao D, Liu Y, Huang j, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis bv synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006;25:1042-52.
49. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helm an LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54:2803-7.